Patent Regulation For UkrAInian Biomedical Data Processing Systems.
1) Overview: Ukraine’s Patent Regulation Framework
Legal Foundation
- Patents in Ukraine are governed primarily by the Law of Ukraine “On the Protection of Rights to Inventions and Utility Models.” This law grants patent owners the exclusive right to exclude others from making, using, selling, or importing the patented invention within Ukraine.
Patentable Subject Matter
- Products and processes — including biomedical devices and data processing systems — can be patented if they are:
- New,
- Involve an inventive step,
- Industrially applicable.
- However, methods of medical treatment and diagnosis (for humans/animals) are not patentable.
Bolar Provision (Critical in Biomedical Context)
- Ukraine has a Bolar exemption — an exception that allows a third party (e.g., generic drug or biosimilar developer) to use the invention to prepare for regulatory approval without causing infringement. This is important where biomedical data or analytics are used to obtain regulatory authorization.
Patent Enforcement
- Patent enforcement happens through Ukrainian courts (general and commercial). Court rulings (especially from the Supreme Court) establish binding case‑law principles.
2) Important Ukrainian Patent Law Principles for Biomedical Systems
A) Exclusive Rights
- A patent gives the owner the exclusive negative right to forbid others from doing certain acts (e.g., making or using a device).
B) Exceptions Are Narrow
- Exceptions — like the “Bolar” research use or export‑only actions — are expressly defined and do not include all acts related to data analytics unless used strictly for regulatory research.
C) Biomedical Data Processing Per Se
- Pure software/data algorithms — including many data processing modes — are generally not patentable unless tied to a technical application (e.g., a specific biomedical device performing analytics). This is consistent with general practice and rejection of abstract business or software claims.
D) War and Patent Term
- Ukrainian courts (especially during martial law) clarified that enforcement rights may extend even after expiration of patents under certain conditions — a unique practical necessity in Ukraine’s context.
3) Detailed Case Laws (Patent Litigation Examples)
Case 1 — Termination of Infringement Prior to Product Launch
Court: Supreme Court of Ukraine, Commercial Cassation (2022)
Facts:
- A company owning patents on a pharmaceutical drug alleged that another entity and the Ministry of Health were infringing by filing regulatory submissions for a product still covered by the patent.
Court Holding:
- The Supreme Court upheld that filing a marketing authorization application that involves making or using a patented invention may itself be an act of infringement. The court ordered cessation of that use and prohibited sale of the infringing product before the patent expired.
This case clarified that pre‑use activities that effectively bring the patented invention into the market chain can be infringing.
Significance:
- It sets a precedent that regulatory filings using patented biomedical inventions can constitute infringement unless exempted (e.g., under Bolar).
Case 2 — Pre‑Bolar Activity Now Potentially Non‑Infringing
Court & Trend: Multiple courts and ongoing disputes (2024–2026)
Context:
- Before the 2025 Bolar reform, many courts treated regulatory filings prior to patent expiry as infringement. Since the Bolar provision expanded in 2025, there is ongoing litigation on whether past acts should now be exempt.
Key Legal Issue:
- Whether Bolar should be applied retroactively to acts completed before the 2025 law.
Emerging Practice:
- Courts are confronting ongoing disputes where a regulatory application was filed before the Bolar amendment but the patent has since expired. Some courts lean toward non‑retroactivity; others are weighing fairness principles.
Outcome & Importance:
- This ongoing development shows how statutory exceptions (Bolar) are shaping the balance between patent protection and early generic/biosimilar entry.
Case 3 — Termination of Infringement Despite Patent Expiry
Court: Commercial Courts, confirmed by Higher Courts
Facts:
- A patent had expired, but disputes arose about whether enforcement actions against infringing use could continue.
Holdings:
- Ukrainian courts sometimes held that even if the patent term expired, the court could enforce remedies for acts that occurred while the patent was valid — particularly if litigation was delayed by external factors (such as wartime extensions).
Significance:
- This ensures that patent owners are not deprived of protection due to procedural delays.
Case 4 — Interim Injunctions in Pharma Patent Disputes
Court/Context:
- In high‑profile pharma cases, the Ukrainian courts — including the Supreme Court — have allowed interim injunctions to stop activities that threaten patent rights while litigation is ongoing. (E.g., brand vs. generics disputes where unauthorized use is alleged.)
Principle:
- Courts can stop infringing activity before final judgment, especially where patent owner demonstrates risk of irreparable harm (e.g., premature generic entry).
Significance:
- This aligns Ukraine with global IP enforcement norms, protecting innovation while litigation proceeds.
Case 5 — Patentability of Biomedical Components vs. Abstract Data Methods
Practical Outcome (Office vs. Courts):
- Patent Office often rejects claims that are purely abstract or non‑technical (e.g., data processing with no physical application). While not a formal court case, such rejections often become judicial appeals.
Legal Reasoning:
- Ukrainian law, like many jurisdictions, requires that software/data systems have a technical character and not merely be an abstract business method.
Example Holding:
- Patent claims directed only at data analysis algorithms without specific biomedical apparatus or technical implementation are often refused — courts uphold such refusals.
Significance:
- This has direct relevance for biomedical data processing systems: pure AI/algorithmic claims must be tied to physical or technical effects (e.g., controlling a medical device).
4) Application to Biomedical Data Processing Systems
If you have a system that processes biomedical data:
Key Legal Points
- You can patent it if it is tied to a technical application — e.g., a device or method that materially improves a biomedical process.
- Pure data analytics or software per se may face rejection unless linked to a device or method with technical effects.
- Enforcement generally protects against unauthorized use, but exemptions (like Bolar) may apply if the data processing is used solely for regulatory or preparatory purposes.
- Courts protect patent owners vigorously, but they also weigh public policy (e.g., access to generics or biosimilars).
5) Practical Takeaways
| Aspect | Ukrainian Patent Law Position |
|---|---|
| Biomedical treatment methods | Not patentable per law. |
| Software/Data processing | Patentable only with tangible technical application. |
| Regulatory research (Bolar) | Exempt from infringement in defined cases. |
| Enforcement | Strong, including interim injunctions & post‑expiry remedies. |
| Case trends | Courts balancing patent rights with public access and fair research use. |
6) Closing Summary
In Ukraine:
- Patent rights are robust and enforceable, especially for biomedical devices and systems.
- Recent reforms (Bolar) are reshaping how regulatory preparations interact with patent rights.
- Courts have developed case‑law confirming that:
- Regulatory filings tied to patented inventions can be infringement.
- Bolar provision is now a key statutory exception.
- Remedies may be available even when royalties/terminations are delayed.
- Interim injunctions protect patent owners.
- Patentable subject matter excludes abstract processes.
RELATED Blog
comments